Skip to content

Erasca, Inc. ERAS Additional Paid-In Capital

Additional Paid-In Capital at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.77B+3.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.83B+75.5%
Eli Lilly logo
Eli LillyLLY
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Arrowhead Research logo
Arrowhead ResearchARWR
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s additional paid-in capital?
Erasca, Inc. (ERAS) reported additional paid-in capital of $1.47B in Q1 2026.
How has Erasca, Inc.'s additional paid-in capital changed year-over-year?
Erasca, Inc.'s additional paid-in capital increased by 22.7% year-over-year, from $1.2B to $1.47B.
What is the long-term trend for Erasca, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Erasca, Inc.'s additional paid-in capital has grown at a 286.4% compound annual growth rate (CAGR), from $1.41M to $1.22B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.